What GLP-1 actually is: an 'incretin' hormone
GLP-1 stands for glucagon-like peptide-1. It's a hormone your small intestine releases within minutes of eating, made by specialized gut cells called L cells from the same parent protein (proglucagon) as the hormone glucagon. Its job is to link 'food just arrived' with your body's response to it.
GLP-1 belongs to a family called incretins — gut hormones that tell the pancreas to release insulin after a meal. The other main incretin is GIP (glucose-dependent insulinotropic polypeptide), which matters for the newer dual-target drugs below. Together, incretins are one of the body's physiologic connections between eating and blood-sugar control (UpToDate; Frontiers in Endocrinology, 2024).
The catch: natural GLP-1 is destroyed almost instantly. An enzyme called DPP-4 breaks it down so fast that its half-life in the blood is only about 1-2 minutes. That's the entire reason the medications had to be engineered — natural GLP-1 is too short-lived to use as a drug.
What 'GLP-1 receptor agonist' means
A receptor agonist is simply a molecule that binds to a receptor and switches it on, imitating the natural hormone. GLP-1 medications are GLP-1 receptor agonists (often shortened to GLP-1 RAs): they lock onto the same GLP-1 receptors your own hormone would, and trigger the same downstream effects.
The key engineering trick is resistance to DPP-4. By tweaking the peptide's structure, drug makers created versions that the DPP-4 enzyme can't chew up quickly. That extends the half-life from minutes to days. Semaglutide, for example, has a half-life of about a week, which is why Ozempic and Wegovy are taken as a once-weekly injection instead of constantly (per the FDA prescribing information).
GLP-1 receptors aren't only in the pancreas. They're found in the stomach, the hypothalamus, and the brainstem, among other tissues — which is why one drug can affect digestion, appetite, and blood sugar at the same time (UpToDate; PMC review of GLP-1 brain signaling).
The four core actions behind every GLP-1 drug
Reviews of GLP-1 pharmacology consistently describe the same set of mechanisms. Here's what activating the GLP-1 receptor does (American Journal of Medicine review, 2025; Frontiers in Endocrinology, 2024):
- Slows gastric emptying — food leaves your stomach more slowly, so you stay physically full longer after a meal and blood sugar rises more gently afterward.
- Reduces appetite via the brain — GLP-1 acts on appetite-control regions (the hypothalamus and the brainstem's nucleus tractus solitarius) to increase the sense of fullness and lower hunger, so you eat less.
- Boosts insulin — only when needed — it enhances glucose-dependent insulin secretion from the pancreas, meaning insulin is released mainly when blood sugar is high.
- Suppresses glucagon — it lowers glucagon, the hormone that tells the liver to dump sugar into the blood, which reduces fasting and after-meal glucose.
How GLP-1 controls blood sugar (and why it rarely causes lows)
GLP-1 drugs lower blood glucose through two levers working together: more insulin when glucose is high, and less glucagon. Insulin moves sugar out of the bloodstream into cells; glucagon does the opposite by prompting the liver to release stored sugar. GLP-1 pushes insulin up and glucagon down, so blood sugar comes down.
The important safety nuance is the phrase glucose-dependent. The insulin-boosting effect is strongest when blood sugar is elevated and fades as glucose returns to normal. Likewise, GLP-1 suppresses glucagon during high or normal blood sugar but not during hypoglycemia (Frontiers in Endocrinology, 2024). This built-in 'off switch' is why GLP-1 receptor agonists used on their own carry a low risk of causing dangerously low blood sugar — though that can change when they're combined with insulin or sulfonylureas, which is a conversation for a prescribing clinician.
This is also why the same medicine helps people with and without diabetes: steadier blood sugar means fewer hunger swings, while the appetite and digestion effects drive weight loss independently.
How GLP-1 drives weight loss — it's mostly the brain
The single biggest driver of weight loss is reduced food intake because of decreased appetite. Research increasingly shows this is a brain effect, not just a stomach effect. In animal studies, blocking GLP-1 receptors specifically in the central nervous system abolishes the weight-loss effect of these drugs, pointing to the brain as the critical site of action (Sisley et al., J Clin Invest 2014; DOI 10.1172/JCI72434).
Inside the brain, activating GLP-1 receptors shifts the balance of appetite signals: it increases 'stop eating' (anorexigenic) signals like POMC and decreases 'keep eating' (orexigenic) signals like neuropeptide Y and AgRP in the hypothalamus. It also engages the brainstem, which receives fullness signals from the gut.
Slowed gastric emptying adds a second, more physical layer of fullness — your stomach stays fuller longer. Some research also links GLP-1 activity to reduced food-reward signaling in the brain's dopamine pathways, which may explain reports of fewer cravings, though this area is still being studied. One well-documented consequence: because the effect depends on ongoing medication, weight regain is common if the drug is stopped (Wilding et al., STEP-1 extension, Diabetes Obes Metab 2022).
Dual and triple agonists: tirzepatide and what's next
The newest medications don't stop at the GLP-1 receptor. Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight management) is a dual agonist — it activates both the GIP receptor and the GLP-1 receptor. GIP is the body's other incretin hormone, and combining the two appears to enhance insulin secretion and weight loss beyond GLP-1 alone (Frontiers in Endocrinology, 2024).
The frontier is triple agonists. Retatrutide, an investigational drug, targets three receptors at once: GLP-1, GIP, and glucagon. That third target is counterintuitive — glucagon normally raises blood sugar — but at the receptor level it's thought to increase energy expenditure and fat breakdown, with the GLP-1 and GIP actions offsetting the glucose rise (Jastreboff et al., retatrutide phase 2, NEJM 2023). Important: retatrutide is not FDA-approved and remains in clinical trials as of 2026.
Do the extra targets translate to more weight loss? In head-to-head-scale trial data: semaglutide 2.4 mg produced about 14.9% average weight loss at 68 weeks (STEP 1, NEJM 2021), tirzepatide reached about 19.5% and 20.9% at the 10 mg and 15 mg doses at 72 weeks (SURMOUNT-1, NEJM 2022), and retatrutide showed substantial reductions of roughly 24% at the highest dose at 48 weeks in a phase 2 trial (NEJM 2023). More targets, so far, has meant more weight loss.
How this differs from older weight-loss drugs
Older prescription weight-loss medications generally worked through different mechanisms — many were appetite suppressants acting on stimulant-type pathways, or drugs that blocked fat absorption in the gut. They also delivered noticeably less weight loss. The STEP 1 investigators noted that previously approved anti-obesity medications produced roughly 4% to 11% weight loss, versus the ~15% seen with semaglutide (NEJM, 2021).
The GLP-1 approach is different because it works with the body's own satiety and blood-sugar systems rather than overriding them with a stimulant. It targets the hormonal signals that regulate hunger and glucose, which is also why the cardiometabolic benefits (blood pressure, cholesterol, blood sugar) tend to travel along with the weight loss in trials.
That said, these are prescription medications with real side effects — nausea and other gastrointestinal effects are the most common, largely a direct result of the slowed digestion — and they require medical supervision. Whether any GLP-1 medication is appropriate for you is a decision for a licensed clinician.
What GLP-1 drugs are NOT: compounded versions and supplements
Two clarifications matter for anyone researching these drugs. First, compounded semaglutide or tirzepatide (custom-mixed by pharmacies) is not an FDA-approved finished drug. The active ingredient may be the same molecule, but compounded products don't go through the FDA's finished-drug approval and quality review, and availability has shifted as shortages resolved. Treat compounded versions as a separate category and discuss them with a clinician and pharmacist.
Second, supplements marketed as 'natural Ozempic' — berberine, for example — are not GLP-1 receptor agonists and are not FDA-approved to treat obesity. The FDA does not evaluate dietary supplements for weight-loss efficacy before they're sold. These products do not work through the verified incretin mechanism described above and are not equivalent replacements for prescription GLP-1 medications. Don't substitute a supplement for a prescribed treatment.
glp1zoom is an independent comparison site. We don't sell, prescribe, or manufacture any medication — we explain how these treatments work and help you compare licensed telehealth providers. Nothing here is medical advice.